Here is the design of a clinical trial:

Official Title: TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis

Included conditions:
- Multiple Sclerosis, Relapsing-Remitting

Study Armgroups:
- {'label': 'Testosterone treatment (Nebido®)', 'type': 'EXPERIMENTAL', 'description': '"Treatment/Nebido®" arm: in this experimental arm, each patient will be injected intramuscularly with 1000 mg / 4 ml of testosterone undecanoate (Nebido®).\n\nTreatment will be injected at baseline, week 6, 18, 30, 42 and 54', 'interventionNames': ['Drug: Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection', 'Procedure: MRI', 'Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities', 'Behavioral: Assessment of disability']}
- {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': '"Placebo" arm: In this arm, each patient will be injected intramuscularly with 4 ml of placebo solution.\n\nPlacebo will be injected at baseline, week 6, 18, 30, 42 and 54', 'interventionNames': ['Drug: Placebo 4 mL Solution for Injection', 'Procedure: MRI', 'Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities', 'Behavioral: Assessment of disability']}

Interventions:
- {'type': 'DRUG', 'name': 'Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection', 'description': 'Active treatment (Nebido® Testosterone Undecanoate ) will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)', 'armGroupLabels': ['Testosterone treatment (Nebido®)']}
- {'type': 'DRUG', 'name': 'Placebo 4 mL Solution for Injection', 'description': 'Placebo will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)', 'armGroupLabels': ['Placebo']}
- {'type': 'PROCEDURE', 'name': 'MRI', 'description': 'Conventional MS sequences (OFSEP recommendations) and unconventional MRI sequences (Baseline, week 30 and 66)', 'armGroupLabels': ['Placebo', 'Testosterone treatment (Nebido®)']}
- {'type': 'BEHAVIORAL', 'name': 'Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities', 'description': 'BICAMS; SF-36 and EQ-5D-3L; MFIS; HADS; WPAI:MS (at baseline, week 30 and 66)', 'armGroupLabels': ['Placebo', 'Testosterone treatment (Nebido®)']}
- {'type': 'BEHAVIORAL', 'name': 'Assessment of disability', 'description': 'EDSS (Baseline, week 30 and 66)', 'armGroupLabels': ['Placebo', 'Testosterone treatment (Nebido®)']}

Primary Outcomes:
- {'measure': 'Change on MRI binary criterion combining thalamic atrophy and modification in transverse diffusivity of lesions', 'description': 'The primary endpoint is a binary criterion comparing the success rate in each treatment group, defined by thalamic atrophy lower than 0.5% and modification in transverse diffusivity of lesions lower than 0.5% per year compared between baseline and week 66 in each group.', 'timeFrame': 'At baseline, week 30 and week 66 (end of study)'}

Please estimate the sample size based on the assumption: 
The success proportions of each group are compared using the posterior distribution of the difference in proportions, with Nebido® declared superior if the posterior probability that the difference between the two proportions is positive exceeds 0.95. The empirical type I error risk is 2%. The power of the test is 80%.
Sample size
        The sample size is calculated using Bayesian methods. Subjects have about 30 to 35% chances of benefiting from an effect of the testosterone treatment with a halt in the development of their pathology. Placebo patients should not benefit from this effect. The sample size calculation is based on the following parameters:
In the experimental group (NebidoÂ®/testosterone), the expected proportion of subjects is modeled with a beta distribution (35, 65), indicating an expected proportion of success of 35%, with a standard deviation of 0.047 (or 4.7%).In the placebo group, the expected proportion of subjects is modeled with a beta distribution (5.95) indicating an expected proportion of success in the order of 5%, with a standard deviation of 0.022 (or 2.2%).
        The success proportions of each group are then compared on the basis of the posterior distribution of the difference in proportions, using McMC methods, and the NebidoÂ® is declared superior if the posterior probability that the difference between the two proportions is positive exceeds 0.95: Pr (pT â pPâ>â0) >â0.95.
        The empirical type I error risk is 2%. With Nâ=â20 subjects per group, over all simulations, the power of the test is of 80%. Thus, 40 subjects meeting eligibility criteria will be randomized, for a total of 80 subjects to be included in the study. The simulations were carried out with R 3.3.1.